Skip to main content
SpringerLink
Log in

Alcohol and Drug Use Disorders

  • Chapter
  • First Online:
Chronic Illness Care

Abstract

Alcohol and other drug use increase the risk for a wide array of health consequences, including substance use disorders (SUDs). Fully 10% of deaths among working adults are due to alcohol, a leading cause of preventable death. SUDs can be short-lived and resolve on their own, or they can be more severe, chronic diseases. Substance use disorders can be identified in clinical care settings by brief questionnaires as brief as single items, and longer questionnaires and interview can provide assessments of levels of risk and severity useful for determining appropriate management. Effective SUD treatments include pharmacotherapy, behavioral modalities, and recovery supports. Treatment should be adapted to severity and response, and medications should not be withheld from those not receiving psychosocial interventions. Other medical and mental health comorbidities must be addressed, as should social ills. Promising models exist for integrating the management of SUDs into general health settings.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Agency for Healthcare Research and Quality. Pharmacotherapy for adults with alcohol-use disorders in outpatient settings; Executive Summary; 2014. Available online at http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=1907. Accessed 18 Jan 2017.

  2. Alderks CE. Trends in the use of methadone and buprenorphine at substance abuse treatment facilities: 2003 to 2011, The CBHSQ Report. Rockville: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2013.

    Google Scholar 

  3. Allensworth-Davies D, Cheng DM, Smith PC, Samet JH, Saitz R. The short inventory of problems – modified for drug use (SIP-DU): validity in a primary care sample. Am J Addict. 2012;21:257–62. https://doi.org/10.1111/j.1521-0391.2012.00223.x.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Baldaçara L, Cogo-Moreira H, Parreira BL, et al. Efficacy of topiramate in the treatment of crack cocaine dependence: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2016;77(3):398–406.

    Article  PubMed  Google Scholar 

  5. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207–25.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Bassetti S, Hoffmann M, Bucher HC, Fluckiger U, Battegay M. Infections requiring hospitalization of injection drug users who participated in an injection opiate maintenance program. Clin Infect Dis. 2002;34(5):711–3.

    Article  PubMed  Google Scholar 

  7. Brown RL, Leonard T, Saunders LA, Papasouliotis O. The prevalence and detection of substance use disorders among inpatients ages 18 to 49: an opportunity for prevention. Prev Med. 1998;27(1):101–10.

    Article  CAS  PubMed  Google Scholar 

  8. California Society of Addiction Medicine (CSAM). What is SBIRT? How do you do it and teach it effectively?; 2009. Available online at http://www.csam-asam.org/sites/default/files/pdf/12_cage_audit_dast.pdf. Accessed 5 Jan 2017.

  9. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. Clin Infect Dis. 2006;43(Suppl 4):S197–215.

    Article  CAS  PubMed  Google Scholar 

  10. Case A, Deaton A. Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Proc Natl Acad Sci U S A. 2015;112(49):15078–83. https://doi.org/10.1073/pnas.1518393112. Epub 2015 Nov 2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs, Treatment Improvement Protocol (TIP) Series 43. HHS Publication No. (SMA) 12-4214. Rockville: Substance Abuse and Mental Health Services Administration; 2005.

    Google Scholar 

  12. Center for Substance Abuse and Treatment. Incorporating alcohol pharmacotherapies into medical practice, Treatment Improvement Protocol (TIP) No. 49. Rockville: Substance Abuse and Mental Health Services Administration; 2009.

    Google Scholar 

  13. Clark RE, Baxter JD, Barton BA, Aweh G, O’Connell E, Fisher WH. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence. Health Serv Res. 2014 Dec;49(6):1964–79.

    PubMed  PubMed Central  Google Scholar 

  14. Clark RE, Baxter JD, Aweh G, O’Connell E, Fisher WH, Barton BA. Risk factors for relapse and higher costs among medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history. J Subst Abus Treat. 2015;57:75–80.

    Article  Google Scholar 

  15. Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94:151–7.

    Article  PubMed  Google Scholar 

  16. DeBeck K, Kerr T, Nolan S, Dong H, Montaner J, Wood E. Inability to access addiction treatment predicts injection initiation among street involved youth in a Canadian setting. Subst Abuse Treat Prev Policy. 2016;11:1.

    Article  PubMed  PubMed Central  Google Scholar 

  17. DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA Jr. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health. 2015;15:3019.

    PubMed  Google Scholar 

  18. D’Onofrio, O’Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, Fiellin DA. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636–44.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Evans E, Li L, Min J, Huang D, Urada D, Liu L, Hser YI, Nosyk B. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006–10. Addiction. 2015;110(6):996–1005.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Ferri M, Amato L, Davoli M. Alcoholics anonymous and other 12-step programmes for alcohol dependence. Cochrane Database Syst Rev. 2006;(3):CD005032.

    Google Scholar 

  21. Fiellin DA, Barry DT, Sullivan LE, Cutter CJ, Moore BA, O’Connor PG, Schottenfeld RS. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2013;126(1):74.e11–7.

    Article  CAS  Google Scholar 

  22. Forman RF, Svikis D, Montoya ID, Blaine J. Selection of a substance use disorder diagnostic instrument by the National Drug Abuse Treatment Clinical Trials Network. J Subst Abus Treat. 2004;27(1):1–8.

    Article  Google Scholar 

  23. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA. 1999;281(14):1318–25.

    Article  CAS  PubMed  Google Scholar 

  24. Gilburt H, Drummond C, Sinclair J. Navigating the alcohol treatment pathway: a qualitative study from the service users’ perspective. Alcohol Alcohol. 2015;50(4):444–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Gossop M, Stewart D, Marsden J. Attendance at narcotics anonymous and alcoholics anonymous meetings, frequency of attendance and substance use outcomes after residential treatment for drug dependence: a 5-year follow-up study. Addiction. 2008;103(1):119–25. Epub 2007 Nov 20.

    Article  PubMed  Google Scholar 

  26. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, McRae-Clark AL, Brady KT. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatr. 2012;169(8):805–12.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Grogan CM, Andrews C, Abraham A, Humphreys K, Pollack HA, Smith BT, Friedmann PD. Treatment and opioid use disorder medications survey highlights differences in medicaid coverage for substance use. Health Aff. 2016;35(12):2289–96.

    Article  Google Scholar 

  28. Guglielmo R, Martinotti G, Quatrale M, Ioime L, Kadilli I, Di Nicola M, Janiri L. Topiramate in alcohol use disorders: review and update. CNS Drugs. 2015;29(5):383–95.

    Article  CAS  PubMed  Google Scholar 

  29. Haddad MS, Zelenev A, Altice FL. Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers. J Urban Health. 2015;92(1):193–213.

    Article  PubMed  Google Scholar 

  30. Hoffman KA, Ford JH, Tillotson CJ, Choi D, McCarty D. Days to treatment and early retention among patients in treatment for alcohol and drug disorders. Addict Behav. 2011;36(6):643–7.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, Cohen A, Ling W. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79–87.

    Article  PubMed  Google Scholar 

  32. Hser YI, Evans E, Huang D, et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016;111(4):695–705.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Humphreys K, Wing S, McCarty D, Chappel J, et al. Self-help organizations for alcohol and drug problems: toward evidence-based practice and policy. J Subst Abus Treat. 2004;26(3):151–8.

    Article  Google Scholar 

  34. Hutchinson E, Catlin M, Andrilla CH, Baldwin LM, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128–33. https://doi.org/10.1370/afm.1595.

    Article  PubMed  PubMed Central  Google Scholar 

  35. John M. Eisenberg Center for Clinical Decisions and Communications Science. Pharmacotherapy for adults with alcohol use disorder in outpatient settings. 2016. In: Comparative effectiveness review summary guides for policymakers [Internet]. Rockville: Agency for Healthcare Research and Quality (US); 2011. Available from: https://phstwlp2.partners.org:2052/books/NBK379844/. Accessed 18 Jan 2017.

  36. Johnson BA, Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des. 2010;16(19):2103–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Kelly JF, Greene MC, Bergman BG. Do drug-dependent patients attending alcoholics anonymous rather than narcotics anonymous do as well? A prospective, lagged, matching analysis. Alcohol Alcohol. 2014;49(6):645–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kelly JF. Is alcoholics anonymous religious, spiritual, neither? Findings from 25 years of mechanisms of behavior change research. Addiction. 2016. https://doi.org/10.1111/add.13590. [Epub ahead of print].

  40. Kerensky T, Walley AY. Opioid overdose prevention and naloxone rescue kits: what we know and what we don’t know. Addict Sci Clin Pract. 2017;12(1):4.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Kidorf M, Neufeld K, Brooner RK. Combining stepped-care approaches with behavioral reinforcement to motivate employment in opioid-dependent outpatients. Subst Use Misuse. 2004;39(13–14):2215–38.

    Article  PubMed  Google Scholar 

  42. Komaromy M, Duhigg D, Metcalf A, Carlson C, Kalishman S, Hayes L, Burke T, Thornton K, Arora S. Project ECHO (extension for community healthcare outcomes): a new model for educating primary care providers about treatment of substance use disorders. Subst Abus. 2016;37(1):20–4.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Korthuis PT, McCarty D, Weimer M, Bougatsos C, Blazina I, Zakher B, Grusing S, Devine B, Chou R. Primary care-based models for the treatment of opioid use disorder: a scoping review. Ann Intern Med. 2016. https://doi.org/10.7326/M16-2149. [Epub ahead of print].

  44. Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, Bushara N, Burakov A, Masalov D, Romanova T, Tyurina A, Palatkin V, Slavina T, Pecoraro A, Woody GE. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012;69(9):973–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. LaBelle CT, Han SC, Bergeron A, Samet JH. Office-based opioid treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts collaborative care model in community health centers. J Subst Abus Treat. 2016;60:6–13.

    Article  Google Scholar 

  46. Lee JD, Friedmann PD, Kinlock TW, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374(13):1232–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, Dossabhoy S, Stein M. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014;174(8):1369–76.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Manwell LB, Fleming MF, Johnson K, Barry KL. Tobacco, alcohol, and drug use in a primary care sample: 90-day prevalence and associated factors. J Addict Dis. 1998;17(1):67–81.

    Article  CAS  PubMed  Google Scholar 

  49. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003;(2):CD002209.

    Google Scholar 

  50. McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689–95.

    Article  CAS  PubMed  Google Scholar 

  51. McNeely J, Cleland CM, Strauss SM, Palamar JJ, Rotrosen J, Saitz R. Validation of self-administered single-item screening questions (SISQs) for unhealthy alcohol and drug use in primary care patients. J Gen Intern Med. 2015;30(12):1757–64.

    Article  PubMed  PubMed Central  Google Scholar 

  52. McNeely J, Wu L, Subramanian G, et al. Performance of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool for substance use screening in primary care patients. Ann Intern Med. 2016;165(10):690–9.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Mee-Lee D. Understanding and utilizing the ASAM placement criteria. NCADD Webinar; 2012. Available online at http://www.naadac.org/assets/1959/2012–03-14_understanding_and_utilizing_asam_webinarslides.pdf. Accessed on 5 Jan 2017.

  54. Monico LB, Gryczynski J, Mitchell SG, Schwartz RP, O’Grady KE, Jaffe JH. Buprenorphine treatment and 12-step meeting attendance: conflicts, compatibilities, and patient outcomes. J Subst Abus Treat. 2015;57:89–95.

    Article  Google Scholar 

  55. National Collaborating Centre for Mental Health, National Institute for Health & Clinical Excellence. Alcohol-use disorders: the NICE guidelines on diagnosis, assessment and management of harmful drinking and alcohol dependence. The British Psychological Society and The Royal College of Psychiatrists; 2011. https://www.nice.org.uk/guidance/CG115/chapter/1-Guidance#interventions-for-alcohol-misuse. Accessed 18 Jan 2017.

  56. NIDA. (2012, December 1). Principles of drug addiction treatment: A research-based guide (Third Edition). Retrieved from https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition on 2017, December 1.

  57. NIDA. Medical consequences of drug abuse; 2012a. Retrieved December 5, 2016 from https://www.drugabuse.gov/related-topics/medical-consequences-drug-abuse

  58. NIDA. Resource guide: screening for drug use in general medical settings; 2012b. Accessed 17 Feb 2017. https://www.drugabuse.gov/publications/resource-guide-screening-drug-use-in-general-medical-settings/nida-quick-screen

  59. O’Malley SS, Rounsaville BJ, Farren C, Namkoong K, Wu R, Robinson J, O’Connor PG. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch Intern Med. 2003;163(14):1695–704.

    Article  PubMed  Google Scholar 

  60. Oslin DW, Lynch KG, Maisto SA, Lantinga LJ, McKay JR, Possemato K, Ingram E, Wierzbicki M. A randomized clinical trial of alcohol care management delivered in Department of Veterans Affairs primary care clinics versus specialty addiction treatment. J Gen Intern Med. 2014;29(1):162–8.

    Article  PubMed  Google Scholar 

  61. Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, Hogg RS, Montaner JS. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84(2):188–94.

    Article  PubMed  Google Scholar 

  62. Paratz ED, Cunningham NJ, MacIsaac AI. The cardiac complications of methamphetamines. Heart Lung Circ. 2016;25(4):325–32. https://doi.org/10.1016/j.hlc.2015.10.019. Epub 2015 Nov 28.

    Article  PubMed  Google Scholar 

  63. Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abus Treat. 2010;39(4):340–52.

    Article  Google Scholar 

  64. Reif S, George P, Braude L, Dougherty RH, Daniels AS, Ghose SS, Delphin-Rittmon ME. Residential treatment for individuals with substance use disorders: assessing the evidence. Psychiatr Serv. 2014;65(3):301–12. https://doi.org/10.1176/appi.ps.201300242.

    Article  PubMed  Google Scholar 

  65. Reif S, Horgan CM, Hodgkin D, Matteucci AM, Creedon TB, Stewart MT. Access to addiction pharmacotherapy in private health plans. J Subst Abus Treat. 2016;66:23–9.

    Article  Google Scholar 

  66. Rosenblatt RA, Andrilla CHA, Caitlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23–6.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Rosenblum A, Cleland CM, Fong C, Kayman DJ, Tempalski B, Parrino M. Distance traveled and cross state commuting to opioid treatment programs in the United States. J Environ Public Health. 2011;2011:948789. https://doi.org/10.1155/2011/948789. Epub 2011 Jul 6.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Rudd RA, Aleshire N, Zibbel JE, Gladden RM. Increases in drug and opioid overdose deaths – United States, 2000–2014. MMWR. 2016;64(50):1378–82. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6450a3.htm?s_cid=mm6450a3_w

    PubMed  Google Scholar 

  69. Rush BR, et al. The interaction of co-occurring mental disorders and recovery management checkups on substance abuse treatment participation and recovery. Eval Rev. 2008;32(1):7–38.

    Article  PubMed  Google Scholar 

  70. Saitz R. Alcohol screening and brief intervention in primary care: absence of evidence for efficacy in people with dependence or very heavy drinking. Drug Alcohol Rev. 2010;29(6):631–40.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Saitz R, Cheng DM, Winter M, Kim TW, Meli SM, Allensworth-Davies D, Lloyd-Travaglini CA, Samet JH. Chronic care management for dependence on alcohol and other drugs: the AHEAD randomized trial. JAMA. 2013;310(11):1156–67. https://doi.org/10.1001/jama.2013.277609.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Saitz R, Palfai TP, Cheng DM, Alford DP, Bernstein JA, Lloyd-Travaglini CA, Meli SM, Chaisson CE, Samet JH. Screening and brief intervention for drug use in primary care: the ASPIRE randomized clinical trial. JAMA. 2014;312(5):502–13.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Samet S, Waxman R, Hatzenbuehler M, Hasin DS. Assessing addiction: concepts and instruments. Addict Sci Clin Pract. 2007;4(1):19–31.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Schwartz RP, Gryczynski J, O’Grady KE, Sharfstein JM, Warren G, Olsen Y, Mitchell SG, Jaffe JH. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. Am J Public Health. 2013;103(5):917–22.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Scott CK, Dennis ML. Recovery management check-ups: an early re-intervention model; 2003. Available online at http://www.williamwhitepapers.com/pr/Recovery%20Management%20Checkup%20Manual%20Scott%20%26%20Dennis%202003.pdf. Accessed 20 Jan 2017.

  76. Shanahan CW, Beers D, Alford DP, Brigandi E, Samet JH. A transitional opioid program to engage hospitalized drug users. J Gen Intern Med. 2010;25(8):803–8.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Shield KD, Parry C, Rehm J. Focus on: chronic diseases and conditions related to alcohol use. Alcohol Res Curr Rev. 2013;35:2.

    Google Scholar 

  78. Singh M, Keer D, Klimas J, Wood E, Werb D. Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized controlled trials. Addiction. 2016;111(8):1337–46.

    Article  PubMed  Google Scholar 

  79. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. Primary care validation of a single-question alcohol screening test. J Gen Intern Med. 2009;24(7):783–8.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med. 2010;170(13):1155–60.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Stahre M, Roeber J, Kanny D, Brewer RD, Zhang X. Contribution of excessive alcohol consumption to deaths and years of potential life lost in the United States. Prev Chronic Dis. 2014;11:E109.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Stoller K, Louie C, Stephens MA. Increasing office-based buprenorphine availability and efficacy through coordination with opioid treatment programs. Poster presented at AAAP 2015 annual meeting. http://www.aatod.org/wp-content/uploads/2016/10/CoOP-poster-Stoller-AAAP2015-pdf1.pdf

  83. Strashny A. Services offered by outpatient-only opioid treatment programs: 2012. 2014. In: The CBHSQ report. Rockville: substance abuse and mental health services administration (US); 2013. Available from: https://www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/books/NBK384662/

  84. Substance Abuse and Mental Health Services Administration. Results from the 2015 National Survey on Drug use and Health. 20857 September 8. Rockville: Center for Behavioral Health Statistics and Quality; 2016.

    Google Scholar 

  85. Ti L, Ti L. Leaving the hospital against medical advice among people who use illicit drugs: a systematic review. Am J Public Health. 2015;105(12):e53–9.

    Article  PubMed  PubMed Central  Google Scholar 

  86. U.S. Department of Veterans Affairs, U.S. Department of Defense. VA/DoD clinical practice guideline for management of substance use disorders (SUD); 2009. www.healthquality.va.gov/guidelines/MH/sud/sud_full_601f.pdf. Accessed 18 Jan 2017.

  87. U.S. Department of Health and Human Services (HHS). Office of the surgeon general, facing addiction in America: the surgeon general’s report on alcohol, drugs, and health. Washington: HHS; 2016.

    Google Scholar 

  88. Wakeman SE, Pham-Kanter G, Donelan K. Attitudes, practices, and preparedness to care for patients with substance use disorder: results from a survey of general internists. Subst Abus. 2016;37(4):635–41.

    Article  PubMed  Google Scholar 

  89. Walley AY, Alperen JK, Cheng DM, Botticelli M, Castro-Donlan C, Samet JH, Alford DP. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1393–8.

    Article  PubMed  PubMed Central  Google Scholar 

  90. White W. Peer-based addiction recovery support: history, theory, practice, and scientific evaluation. Chicago: Great Lakes Addiction Technology Transfer Center and Philadelphia Department of Behavioral Health and Mental Retardation Services; 2009.

    Google Scholar 

  91. Yarborough BJ, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA. Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis. Drug Alcohol Depend. 2016;160:112–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Lee JD, Nunes EV, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphinenaloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2017.; (published online Nov 14.)

    Google Scholar 

  93. Tanum L, Solli KK, Latif Z-e-H, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N. The Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid DependenceA Randomized Clinical Noninferiority Trial. JAMA Psychiatry. 2017. https://doi.org/10.1001/jamapsychiatry.2017.3206. Published online October 18

  94. Watkins KE, Ober AJ, Lamp K, Lind M, Setodji C, Osilla KC, Hunter SB, McCullough CM, Becker K, Iyiewuare PO, Diamant A, Heinzerling K, Pincus HA. Collaborative care for opioid and alcohol use disorders in primary care the SUMMIT tandomized clinical trial. JAMA Intern Med. 2017;177(10):1480–8. https://doi.org/10.1001/jamainternmed.2017.3947.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

    Sarah E. Wakeman

  2. Department of Community Health Sciences (CHS), Department of Medicine, Boston University Schools of Public Health and Medicine, Boston Medical Center, Boston, MA, USA

    Richard Saitz

Authors
  1. Sarah E. Wakeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Saitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah E. Wakeman .

Editor information

Editors and Affiliations

  1. Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

    Timothy P. Daaleman

  2. Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

    Margaret R. Helton

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wakeman, S.E., Saitz, R. (2018). Alcohol and Drug Use Disorders. In: Daaleman, T., Helton, M. (eds) Chronic Illness Care. Springer, Cham. https://doi.org/10.1007/978-3-319-71812-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-71812-5_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-71811-8

  • Online ISBN: 978-3-319-71812-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation